-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
New specific guidance on dose-dependent prolongation of QTc with ondansetron.
-
Letters were sent about ibrutinib, daclizumab, aflibercept, valproate medicines, and arsenic trioxide.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram ad…
-
Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
Reports of reconstituted solution leaking from some models of extension sets and pumps.
-
Reminder to monitor and manage weight, glucose, and lipid levels.…
-
A large study has shown no safety issues of concern relating to the use of metformin during pregnancy. The licence for metformin now reflects that it can be considered for use during pregnancy and the periconceptional phase …
-
Alerts were issued about CME T34 and T34L (T60) ambulatory syringe pumps, Cardinal Health tympanic thermometers, t:slim X2 insulin pump, and Mavidon skin preparation electrode gels.
-
Test for raised ketones in patients with ketoacidosis symptoms, even if plasma glucose levels are near-normal.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. Includes a recent recall of Accupro (quinapril hydrochloride) and advice on Xagrid (anagrelide hydrochloride…
-
New recommendations following a recent clinical trial which found that in patients with type 1 hepatorenal syndrome terlipressin may cause serious or fatal respiratory failure at a frequency higher than previously known, and…
-
…Other alerts were issued about paracetamol tablets, docetaxel injection, Baxter potassium-chloride-containing intravenous infusions, and Emerade adrenaline auto-injectors.…
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
-
A signal of increased lower limb amputation (primarily of the toe) in people taking canagliflozin compared with placebo in a clinical trial in high cardiovascular risk patients is currently under investigation.
-
A summary of letters and drug alerts recently sent to healthcare professionals, including recommendations to reduce handling errors with leuprorelin-containing depot medicines.
-
Risk of developing progressive multifocal leukoencephalopathy (PML) associated with natalizumab is increased in patients who have had previous immunosuppressant therapy.
-
…Calcium gluconate injection packed in small-volume glass containers is now contraindicated for use as repeated or prolonged treatment, including as an intravenous infusion, in children younger than 18 years and in patients with renal impairment.…
-
…Alerts were issued about irbesartan, amoxicillin, atropine sulfate, and paracetamol infusion.
-
To be used only in patients with acute blood loss and when crystalloids alone are not sufficient.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a patient safety alert on mexiletine hydrochloride.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages. The article also includ…
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices and details of two recent MHRA National Patient Safety Alerts to remove from service Philips Health Systems V…
-
Letters were sent about eluxadoline (Truberzi), fingolimod (Gilenya), Bleo-Kyowa (bleomycin sulphate), Buccolam (midazolam), and ERWINASE.
-
An alert was recently issued about Prismaflex haemofiltration machines.
-
Check pumps after MRI.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
Alerts were recently issued about BD Alaris/Asena syringe pumps and Maxter Catheters nasogastric (NG) feeding tubes.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
Letters were sent about Arsenic Trioxide (Trisenox), Uptravi▼ (selexipag), DepoCyte (cytarabine), Cinryze▼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).
-
In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.
-
Letters were sent about azithromycin, Lynparza▼(Olaparib), Xgeva▼ (denosumab), Lymphoseek (tilmanocept), ReoPro (abciximab) and dolutegravir; you still have time to complete a quick survey to tell us your views on the way me…
-
With the exception of medicines containing zidovudine, stavudine, or didanosine, product information will no longer include warnings on fat redistribution or lactic acidosis.
-
Letters were sent about ellaOne, ERWINASE, Eperzan▼, Ocaliva▼, Velcade, Esmya, and Bleo-Kyowa.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
The risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab increases after 2 years of therapy. Patients with multiple sclerosis should be informed of the risk before treatment, and again after 2…
-
Clinical trials have reported an increased risk of renal dysfunction and mortality in critically ill or septic patients who received hydroxyethyl starch (HES) compared with crystalloids.
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
The Food and Drug Administration (FDA) has received 35 reports of chondrolysis involving patients given continuous intra-articular infusions of local anaesthetics.
-
We have issued a National Patient Safety Alert following serious reports of harm associated with insulin leakage during use of the Accu-Chek Insight Insulin pump with NovoRapid PumpCart prefilled insulin cartridges. Patients…